IDH2 and acute myeloid leukemia: Interestingly, the two patients in our cohort who had an IDH2 mutation at diagnosis and two of the four patients with mutated NPM1 at diagnosis progressed to AML, while the other two patients with NPM1 mutations received chemotherapy followed by alloSCT despite having <20% blasts, following previous recommendations [51] that prognosis is improved with more intense therapy.